Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR (2002) Lancet 359: 118-23 COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) Lancet 360: 1071-3 Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, Marnett LJ (2010) J Biol Chem 285: 34950-9 Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC (2010) PLoS One 5: e9340 COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J (2003) Pharmacoepidemiol Drug Saf 12: 67-70
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.